The potential of circHIPK3 as a biomarker in chronic myeloid leukemia

The potential of circHIPK3 as a biomarker in chronic myeloid leukemia

Chronic myeloid leukemia (CML) is a myeloproliferative disorder characterized by leukocytosis and left shift. The primary molecular alteration is the BCR::ABL1, chimeric oncoprotein with tyrosine kinase activity, responsible for the initial oncogenesis of the disease. Therapy of CML was revolutioniz...

Full description

Bibliographic Details
Main Authors: Eduardo Wandame Gomez, Laura Berti De Paula, Rafael Diogo Weimer, Alessandra Helena da Silva Hellwig, Grazielle Motta Rodrigues, Ana Paula Alegretti, Jarbas Rodrigues de Oliveira
Format: Article
Language:English
Published: Frontiers Media S.A. 2024-03-01
Series:Frontiers in Oncology
Subjects:
chronic myeloid leukemia
biomarker
ncRNA
circRNA
CircHIPK3
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2024.1330592/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2024.1330592/full

Similar Items